Spots Global Cancer Trial Database for Clinical Study of Apatinib and XELOX Combination Regimen to Treat Colorectal Cancer Patients

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Clinical Study of Apatinib and XELOX Combination Regimen to Treat Colorectal Cancer Patients

Official Title: A Phase II Clinical Trial Study on Apatinib and XELOX Combination Regimen in the First-line Treatment of End-stage Colorectal Cancer Patients

Study ID: NCT02829385

Conditions

Colorectal Neoplasms

Interventions

Apatinib and XELOX combined treatment group

Study Description

Brief Summary: This study makes an observation over the objective response rate of Apatinib and XELOX combination regimen in the first-line treatment of metastatic colorectal cancer. All the participants will receive the treatment of Apatinib and XELOX combination regimen.

Detailed Description: XELOX chemotherapy is an effective therapy for metastatic colorectal cancer as first-line treatment. Apatinib is a small-molecule tyrosine kinase inhibitor (TKI) that highly selectively binds to and strongly inhibits vascular endothelial growth factor receptor 2 (VEGFR-2), with a decrease in VEGF-mediated endothelial cell migration, proliferation, and tumor microvascular density. A phase II trail of Apatinib has been demonstrated that Apatinib is safe to treat the metastatic colorectal cancer and the disease control rate can reach 50%.